

Measurement of serum Inhibin B as a predictive evaluation of ovarian response following ovulation induction program in intrauterin insemination

Nawal Khairy AL-Ani, Layla Khudur Ghalib.

Abstract:

Background:

The evaluation of ovarian reserve has been, and still, the focus of substantial clinical research. The assessment of ovarian reserve is valuable for determining stimulation protocols, and because of limited predictive value of age alone, or other passive hormonal analysis in estimating response to the exogenous stimulation, Dynamic research was done on serum inhibin B.

Objective:

Measurement of serum inhibin B as a predictive evaluation of early ovarian response following ovulation induction program in intrauterine insemination(IUI).

Materials and Methods:

Thirty couples were involved in IUI program. They divided into two groups: group (1) 15 women were treated by Gonadotropin(Gn) recombinant follicle -stimulating hormone (rFSH). While group (2), 15 women were treated by Clomiphene citrate (CC). Treatment started at day 3 of the menstrual cycle. Serial hormonal profile tests namely; inhibin B, Estadiol (E2), Follicle-stimulating hormone (FSH), Luteinizing hormone (LH) were done at days 3, 7 of the menstrual cycle and the day of human chorionic gonadotropin hormone (hCG) injection with recurrent ultrasonography (U/S) to confirm the number and development of the follicles.

Results:

There was a significant difference in the level of inhibin B ($P < 0.05$) between day3 and 7 of the cycle with the mean of the follicle number 1.67 ± 0.18 in group(1), while in group (2) there was a non significant difference ($P > 0.05$) in the level of inhibin B between day 3 and 7 of the cycle with the mean of the follicle number 2.14 ± 0.17 . Percentage of pregnancy rate in IUI in this study was 19.23%.Percentage of pregnancy rate in group (1) was 25% ,while in group (2) was 14.28% ,but there is a significant difference ($P < 0.05$) in the pregnancy rate between the two groups.

Conclusion:

It was concluded that serum inhibin B obtained at day 7(day 5 of (Gn) therapy) offers an early and accurate prediction of ovarian response to (Gn) stimulation while there was no significant change in the level of inhibin B between day 3 and 7 of the cycle in patients treated by CC .

Key Words: Inhibin B, Gonadotropin, Clomiphene Citrate, IUI.

Introduction

The hormonal control of ovarian function by gonadotropins plays a key role in the physiologic process of follicular growth and differentiation, that is selection of a single dominant follicle followed by a mono ovulation⁽¹⁾. A patient's ovarian response to stimulation medicine is mainly determined by her ovarian reserve, which comprises the quantity and functional capacity of follicles. Pre-evaluation of ovarian reserve and prediction of ovarian response would provide a valuable means of assisting clinicians in selecting appropriate dose of therapeutic agents for each patient⁽²⁾. Traditional criteria used to predict ovarian response to ovarian stimulation drug include the patient's age, baseline serum concentration of hormones such as (FSH), (LH), Estradiol (E₂), FSH to LH ratio⁽³⁾. Inhibin B was suggested as an early sensitive predictor of ovarian reserve⁽⁴⁾.

Inhibins are dimeric polypeptides produced by granulosa cells and composed of an α -subunit along with a β A-subunit (inhibin A) or a β B-subunit (inhibin B). Inhibin B concentrations rise across the luteal-follicular transition and peak in the mid follicular phase, suggesting that they are secreted by the developing cohort of follicles, and may mark the number or quality of developing follicles at the baseline⁽⁵⁾. With the better understanding of the control, synthesis and secretion of the inhibins and their potential endocrine role in the menstrual cycle, attention has turned to the possibility of this family of peptides to provide a more direct index of ovarian reserve^(6,7).

Therefore, this study was designed to identify prospectively the values of basal and dynamic measurements of inhibin B following ovarian stimulation therapy (recombinant FSH or CC) in predicting early ovarian response and pregnancy outcome in IUI.

Materials and Methods

All the females age involved in this study were (19 -39) years old with regular menstrual cycle excluding poly cystic ovarian syndrome (PCOS), FSH<15(mIU/mL), and normal prolactin level. They are examined generally and gynecological after thorough history taking⁽⁸⁾. Assessment of male infertility by the physician is based on a patient's history, physical examination, and semen analysis⁽⁹⁾.

Group (1) treated by Gonal- F(R) 75 IU on alternate day⁽¹⁰⁾, while group (2) treated by CC tablet containing 50 mg/ (1 \times 2)/ daily from day 3 to day7 of the menstrual cycle⁽¹¹⁾. The ultrasonography study was performed at day 3 of the cycle to detect antral follicle number and diameter in the two groups, and any uterine abnormalities⁽¹²⁾.

Diameter of the follicle (s) was monitored by serial examinations of vaginal ultrasound. At least one or two mature (dominant) follicles were recognized about 17 – 20 mm, supplemented by the ovulatory hormone Ovitrelle^(R) (Merck/Serono) (hCG) 250 μ g, 6500IU was used to induce ovulation. *In vitro* Activation Technique: Simple layer procedure was performed for the semen samples preparation that involved in this study. Then IUI was done by IUI catheter after 34 -36hr⁽¹³⁾

Hormonal assays, serum levels of Inhibin B (pg/mL), FSH (mIU/mL), LH (mIU/mL) and E₂ (pg/mL) were measured by using ELISA (enzyme-linked immunosorbent assay) at days (3,7 of the cycle and the day of hCG injection).

Results

The basal level of inhibin B in group (1) at day 3 of the menstrual cycle mean \pm SE was 40.94 \pm 1.99, at day 7 of the cycle, the mean \pm SE of inhibin B was 50.88 \pm 1.87. At day of hCG injection, the mean \pm SE was 40.35 \pm 3.11. There is statistically significant difference (P<0.05) among the three values as shown in Figure (1).

The basal level of inhibin B mean \pm SE in group (2) at day 3 of the menstrual cycle was 39.69 \pm 3.41, at day 7 of the cycle, it was 36.71 \pm 3.61, while at day of hCG injection, the mean \pm SE was 31 \pm 4.25. There is statistically no significant difference (P>0.05) among the three values as shown in figure (2).

The basal level of E2 in group (1) at day 3 of the menstrual cycle mean \pm SE was 42.53 \pm 3.20, at day 7 of the cycle, the mean \pm SE was 97.18 \pm 13.90. At day of hCG injection, the mean \pm SE was 203.52 \pm 28.47. There is statistically highly significant difference P<0.001 among the three values as shown in figure (3)

The level of E2 in group (2) at day 3 of the menstrual cycle mean \pm SE was 50.493.97 \pm . At day 7 of the cycle, the mean \pm SE was 118.24 \pm 15.45. While at day of hCG injection, the mean \pm SE was 342.46 \pm 64.30. There is statistically highly significant difference P<0.001 among the three values as shown in figure (4).

Regarding the clinical characteristic of patients in two groups there were significant difference in follicle number as shown in Table (1).




Figure (1)inhibin B level changes in group (1) after treatment by rFSH




Figure (2)inhibin B level changes in group (2) after treatment by (cc)




Figure (3) E2 level changes in group (1) after treatment by rFSH




Figure (4) E2 level changes in group (2) After treatment by (CC)

Table (1) Comparison clinical characteristic of patients in the two groups(1) patients treated by rFSH ,(2) patients treated by CC.

| Characteristics | Group 1 | Group 2 | | LSD | P value |
|------------------------|--------------|--------------|--|------|----------|
| Age | 29.50 ±1.64A | 29.07± 1.78A | | 6.89 | 0.129 NS |
| BMI | 27.02± 1.00A | 28.95± 0.53A | | 4.37 | 0.161NS |
| Antral follicle number | 7.83± 0.53A | 9.07 ±0.70A | | 3.37 | 0.198 NS |
| Follicle number | 1.67+ 0.18B | 2.14± 0.17B | | 2.45 | 0.007* |
| Endometrial thickness | 8.99± 0.17A | 8.81 ±0.18A | | 3.24 | 0.201NS |

NS-non significant *-significant (P<0.05)

Table(2): Comparison between the pregnancy outcome and (hormonal levels of inhibin B, E₂ , and various variables) in group(1) .

| Parameter | Pregnancy | No | Mean | SEM | P value |
|-----------------------------|-----------|----|---------|-------|---------|
| Age | Yes | 3 | 26.00 | 3.51 | 0.236 |
| | No | 9 | 30.67 | 1.80 | |
| Antral follicle | Yes | 3 | 9.33 | 1.33 | 0.107 |
| | No | 9 | 7.33 | 0.50 | |
| Follicle number | Yes | 3 | 2.00 | 0.57 | 0.329 |
| | No | 9 | 1.56 | 0.17 | |
| Endometrial thickness | yes | 3 | 8.9333 | 0.26 | 0.856 |
| | No | 9 | 9.0111 | 0.22 | |
| inhibinCD3 | Yes | 3 | 47.9933 | 1.87 | 0.006* |
| | No | 9 | 38.5911 | 1.40 | |
| inhibinCDV | Yes | 3 | 55.8967 | 1.37 | 0.127 |
| | No | 9 | 49.2078 | 2.21 | |
| Inhibin B day hCG injection | Yes | 3 | 42.7000 | 4.13 | 0.685 |
| | No | 9 | 39.5767 | 4.00 | |
| E2-CD3 | Yes | 3 | 47.6533 | 5.19 | 0.382 |
| | No | 9 | 40.8322 | 3.88 | |
| E2-CD7 | Yes | 3 | 96.4733 | 32.99 | 0.978 |
| | No | 9 | 97.4233 | 16.23 | |
| E2-Day of hCG injection | Yes | 3 | 244.73 | 71.31 | 0.430 |
| | No | 9 | 189.79 | 31.11 | |

Group(1)- patients treated by rFSH

• P<0.05 significant difference

Table(3): Comparison between the pregnancy outcome and (hormonal levels of inhibin B, E₂, and various variables) in group(2)

| Parameter | Pregnancy | N | Mean | SEM | P value |
|-------------------------|-----------|----|--------|--------|---------|
| Age | Yes | 2 | 34.50 | 2.50 | 0.227 |
| | No | 12 | 28.17 | 1.93 | |
| Duration of infertility | Yes | 2 | 5.00 | 1.00 | 0.761 |
| | No | 12 | 4.58 | 0.51 | |
| Antral follicle | Yes | 2 | 10.00 | 2.00 | 0.612 |
| | No | 12 | 8.92 | 0.78 | |
| Follicle number | Yes | 2 | 2.50 | 0.50 | 0.433 |
| | No | 12 | 2.08 | 0.19 | |
| Endometrial thickness | Yes | 2 | 9.25 | 0.55 | 0.345 |
| | No | 12 | 8.74 | 0.19 | |
| Inhibin B- CD3 | Yes | 2 | 36.69 | 5.76 | 0.735 |
| | No | 12 | 40.19 | 3.92 | |
| InhibinB- CD7 | Yes | 2 | 34.24 | 3.34 | 0.792 |
| | No | 12 | 37.12 | 4.20 | |
| InhibinB-day hCG | Yes | 2 | 24.58 | 10.67 | 0.519 |
| | No | 12 | 32.82 | 4.72 | |
| E2-CD3 | Yes | 2 | 53.53 | 3.97 | 0.769 |
| | No | 12 | 49.99 | 4.61 | |
| E2-CD7 | Yes | 2 | 182.07 | 68.21 | 0.092 |
| | No | 12 | 107.60 | 13.66 | |
| E2-Day hCG | Yes | 2 | 704.64 | 326.36 | 0.014* |
| | No | 12 | 282.10 | 42.06 | |

Group(2)- patients treated by CC.

* - P<0.05 significant difference

Discussion

In group (1),

There was a significant difference (P< 0.05) in the level of inhibin B among day 3, 7 of the cycle and day of hCG injection. This result is in agreement with the those authors^(5,14) reported that inhibin B is the predominant inhibin in the small antral follicles rising in the early to mid follicular phase, then falling throughout the late follicular phase and remaining low for the duration of the luteal phase.

In this study, it was detected that E₂ at day of hCG injection is more sensitive index of ovarian response to Gn stimulation, this result agrees with the other authors⁽¹⁵⁾ who reported that, during ART cycle, plasma E₂ measurements are routinely used to calibrate the Gn doses in conjunction with data obtained by ultrasound, and its directly related to follicular size and that the contribution of mature

follicles to E₂ output may be estimated at about 200pg/ml. While there is a better correlation of inhibin B during the mid-follicular phase, when granulosa cell function is strongly dependent on FSH⁽¹⁶⁾.

There was significant difference (P<0.05) of LH level among day 3, day 7 and the day of hCG injection, this is due to the fact that sign of LH measurements during Gn stimulation are usually restricted to the detection of the endogenous LH surge, specially required for women undergoing IUI⁽¹⁵⁾.

2-Group(2) received clomiphene citrate

There was no significant difference (P>0.05) in the level of inhibin

B among day 3, day 7 of the cycle and the day of hCG injection, also no significant difference ($P>0.05$) in the level of FSH among day 3, 7 and the day of hCG injection due to the fact that clomiphene citrates long retention within tissues, so physiologic response of the developing follicles is assumed to overcome the influence of CC on the hypothalamic-pituitary axis and reduce FSH levels to normal range by cycle day 10 as shown in figure (2-4)⁽¹⁷⁾. Our results agree with the facts⁽¹⁸⁾ reported that the rate of follicular growth and number of follicles in patient who received CC from cycle days 5- 9 was significantly better than the group who received CC from cycle day 2-6.

Pregnancy outcome in IUI

There was only significant correlation between basal inhibin B level at day 3 of the cycle and pregnancy rate in group (1), this result agrees with that found by those authors⁽⁴⁾, reported that inhibin B serve as a better and direct measure of ovarian reserve. There was a significant correlation between the pregnancy outcome and serum E_2 level at day of hCG injection in group(2), this is in agreement with those authors⁽¹⁵⁾ reported that E_2 is more sensitive index of ovarian response to Gn stimulation during ART cycle.

Percentage of pregnancy rate in IUI in this study was 19.23%. Percentage of pregnancy rate in group (1) was 25% ,while in group (2) was 14.28% with the fact that using swim up *in vitro* activation techniques of the semen samples, gets safely separation of spermatozoa based on their motility and morphology and gained significantly higher percentage of motility⁽¹⁹⁾, but there is significant difference ($P<0.05$) in the pregnancy rate between the two groups, this is agree with those authors⁽²⁰⁾ found that in IUI with the use of rFSH get higher pregnancy rate.

References

- 1-Hugues JN, Durnerine IC. Endocrine characteristics of ART cycles. In : David K Gardner, Ariel Weissman, Colin M Howles *et al.* Editors. Text book of Assisted Reproductive Technologies. 3rd ed. United Kingdom. Informa press.2009.pp.511- 538.
- 2- Navot D, Rosenwaks Z and Margalioth EJ. Prognostic assessment of female fecundity. *Lancet*.1987; 330(8560):645 -647.
- 3- Ravhon A, Lavery S, Michael S, *et al.* Dynamic assays of inhibinB and estradiol following buserelin acetate administration as predictors of ovarian response in IVF. *Hum.Reprod.* 2000; 15(11):2297- 2301.
- 4-Seifer DB, Lambert-Messerlian G, Hogan JW, *et al.* Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. *Fertil. Steril.* 1997; 67(1):110- 11
- 5-Groome NP, Illingworth PJ, O'Brien . Measurement of dimeric inhibin-B throughout the human menstrual cycle . *J. Clin. Endocrinol. Metab.* 1996; 81(4):1401- 1405.
- 6-Shanthi MK, Harris S, Hugh MG, *et al.* Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? *Int. J. Obstet. Gynaecol.*2004; 111:1248- 1253.
- 7-Laven JS and Fauser BC. Inhibins and adult ovarian function. *Mol. Cell. Endocrinol.* 2004; 225(1-2):37-44
- 8-Rao KA, Brnsden PR, Sathanathan AH . The infertility manual. 2nd edition. New Delhi: jaypee brother's medical publishers.2004. (p) Ltd. 2.
- 9- Nikolai M. and Malcetus. White head.Female Reproductive Health. New York .ISBN.2005.pp.104- 123.
- 10-Richard P.D, Peter R. and Roman P. Insemination technique and insemination complications .In: Richard P. Dickey, Peter R and Roman P. Intrauterine insemination and ovulation induction 1st ed.. NewYork . Cambridge University Press, 2010. Pp.109 -118.
- 11-Lidor G.M, Cohen S, and Mashiach S.Management of women with polycystic ovary syndrome who experience premature luteinization during CC treatment. *Fertil. Steril.*2000;74:749 -752.
- 12-Hargreave.T and Mahmoud.A. Manual for the Standardized Investigation, Diagnosis and Management of the Infertile Male.Cambridge University.2000.
- 13- Felyyeh E. Comparative study of ovulation induction and hormone profile using Tamoxifen, Clomiphene citrate and Dexamethasone in infertile women. submitted to the High Institute of Infertility Diagnosis and Assisted Reproductive Technology. Al- Nahrain university, in Partial Fulfillment of the Requirements for the Degree of High Diploma in Assisted Reproductive Technologies. 2010.
- 14-- Eldar-GevaT, Margalioth EJ, Ben C.A,*et al.* Serum inhibin B levels measured early during FSH administration for IVF may be of value in predicting the number of oocytes to be retrieved in normal and low responders. *Hum Reprod.* 2002; 17:2331–2337.
- 15-Zeev S., Colin M.H. Drugs used for ovarian stimulation: clomiphene citrate, aromatase inhibitors, metformin, gonadotropins, gonadotropin – releasing hormone analogs, and recombinant gonadotropins.In: David K Gardner, Ariel Weissman, Colin M Howles, *et al.*, Textbook of Assisted Reproductive Technologies 3rd ed.. UK. Replika Press. 2009 pp469-488.
- 16--Kwee J, Elting MW, Schats R, *et al.* Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. *Hum Reprod .* 2003;18:1422–1427.
- 17-Schorge JO ,Schaffer JI, Halvorson LM, *et al.* Williams Gynecology .2008, [http:// www.accessmedicine.com](http://www.accessmedicine.com).
- 18-Hussain SM, Al-Ansari SAM, and Al- Barazanichi M R. Follicular growth in term of patient age and cycle day of clomiphene citrate. Asian Symposium on animal biotechnology (Kamiina, Japan) 4th.1998; 7-9. pp.226 -231.
- 19-Al- Dujaily SS, Al-Janabi AS and Nori M. Effect of Glycyrrhiza extract on *in vitro* sperm activation of asthenospermic patients.*J Babylon University*2006,11(3):477 -483.
- 20-Reindollar RH, Regan MM, Neumann PJ, *et al.*, Arandomized clinical trial to evaluate optimal treatment for unexplained infertility .*Fertil. Steril.*2010;94(3):888- 99.